Anticholinergic therapy for airway diseases

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

Original languageEnglish (US)
Pages (from-to)2565-2572
Number of pages8
JournalLife Sciences
Volume68
Issue number22-23
DOIs
StatePublished - Apr 27 2001
Externally publishedYes

Fingerprint

Cholinergic Antagonists
Asthma
Muscarinic M2 Receptors
Pulmonary diseases
Bronchoconstriction
Rhinitis
Chronic Obstructive Pulmonary Disease
Cholinergic Agents
Therapeutics

Keywords

  • Asthma
  • COPD
  • Ipratropium
  • Rhinitis
  • Tiotropium

ASJC Scopus subject areas

  • Pharmacology

Cite this

Anticholinergic therapy for airway diseases. / Jacoby, David; Fryer, Allison.

In: Life Sciences, Vol. 68, No. 22-23, 27.04.2001, p. 2565-2572.

Research output: Contribution to journalArticle

@article{bedd23f73bc74a11bf9eae6815829ac0,
title = "Anticholinergic therapy for airway diseases",
abstract = "Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.",
keywords = "Asthma, COPD, Ipratropium, Rhinitis, Tiotropium",
author = "David Jacoby and Allison Fryer",
year = "2001",
month = "4",
day = "27",
doi = "10.1016/S0024-3205(01)01053-0",
language = "English (US)",
volume = "68",
pages = "2565--2572",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "22-23",

}

TY - JOUR

T1 - Anticholinergic therapy for airway diseases

AU - Jacoby, David

AU - Fryer, Allison

PY - 2001/4/27

Y1 - 2001/4/27

N2 - Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

AB - Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

KW - Asthma

KW - COPD

KW - Ipratropium

KW - Rhinitis

KW - Tiotropium

UR - http://www.scopus.com/inward/record.url?scp=0035957576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035957576&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(01)01053-0

DO - 10.1016/S0024-3205(01)01053-0

M3 - Article

C2 - 11392627

AN - SCOPUS:0035957576

VL - 68

SP - 2565

EP - 2572

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 22-23

ER -